Drug Trial Radar · NCT05712187
Phase 2b Study of ALTO-100 in MDD
Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
301
Actual
Start
Jan 10, 2023
Primary completion
Sep 5, 2024
Study completion Oct 24, 2024
Sponsor
- Lead sponsor
- Alto NeuroscienceIndustry
- Sponsor type
- Industry
- First posted
- Feb 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.
Conditions
- Major Depressive Disorder
Interventions
ALTO-100Drug
ALTO-100 tablet BID
PlaceboDrug
Placebo tablet BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess efficacy of ALTO-100 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change from Day 1 to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.Time frame: Change assessed from Day 1 to Week 6
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Site 174
Birmingham, Alabama
Site 173
Huntsville, Alabama
Site 136
Chandler, Arizona
Site 139
Little Rock, Arkansas
Site 141
Costa Mesa, California
Site 118
Fresno, California
Site 181
Imperial, California
Site 182
Oceanside, California
Site 188
Oceanside, California
Site 179
Rancho Cucamonga, California
Site 116
Sacramento, California
Site 185
Centennial, Colorado
Site 186
Brooksville, Florida
Site 204
Jacksonville, Florida
Site 205
Orlando, Florida
Site 212
Tampa, Florida
Site 213
Tampa, Florida
Site 137
Carmel, Indiana
Site 151
Baltimore, Maryland
Site 108
Jackson, Mississippi
Site 171
Jackson, Mississippi
Site 142
Lincoln, Nebraska
Site 144
Las Vegas, Nevada
Site 178
Albuquerque, New Mexico
Site 184
Brooklyn, New York
Site 180
New York, New York
Site 210
New York, New York
Site 175
Westlake, Ohio
Site 157
North Charleston, South Carolina
Site 183
Memphis, Tennessee
Site 147
Fort Worth, Texas
Site 120
Houston, Texas
Site 172
Houston, Texas
Site 121
Draper, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.